Yardley, PA
Almac Clinical Technologies announced that it has been named one of the Best Places to Work in PA for 2009. The awards program, created in 2000, is one of the first statewide programs of its kind in the country. It consists of a public/private partnership between Team Pennsylvania Foundation, the Pennsylvania Department of Community and Economic Development, the Pennsylvania Chamber of Business and Industry and the Central Penn Business Journal.
This survey and awards program was designed to identify, recognize and honor the best places to be employed in Pennsylvania. It is intended to acknowledge companies that have established a dynamic and productive working environment for their employees.
Companies from across the state entered the two-part process to determine the 100 Best Places to Work in PA. The first part consisted of evaluating each nominated company's workplace policies, practices, philosophies, systems and demographics. The second part consisted of an employee survey to measure the employee experience. The combined scores of both parts determined the top companies and the final ranking. Best Companies Group managed the overall registration and survey process.
Almac Clinical Technologies will be recognized at the Best Places to Work in PA evening awards ceremony on Tuesday, December 1, 2009, at the Hershey Lodge & Convention Center in Hershey, PA. Rankings will be revealed at the ceremony.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.